Good clinical practice: a nuisance, a help or a necessity for clinical pharmacology?
Version of Record online: 14 JAN 2003
British Journal of Clinical Pharmacology
Volume 55, Issue 1, pages 1–5, January 2003
How to Cite
Sweatman, J. (2003), Good clinical practice: a nuisance, a help or a necessity for clinical pharmacology?. British Journal of Clinical Pharmacology, 55: 1–5. doi: 10.1046/j.1365-2125.2003.01713.x
- Issue online: 14 JAN 2003
- Version of Record online: 14 JAN 2003
- Received 18 June,accepted 2 September.
- clinical protocol;
- clinical trial directive;
- ethics committees;
- good manufacturing practice;
- ICH GCP;
- quality assurance;
- research governance framework;
- Resuscitation Council;
- validated computers;
This article reviews the impact of good clinical practice (GCP) on clinical pharmacology with particular reference to the new European Union Clinical Trial Directive. The Directive will be applied to both commercial and noncommercial studies on medicinal products for human use. The Directive requires that GCP should be used in all clinical trials except noninterventional studies. GCP is likely to follow the International Conference on Harmonization GCP guidelines in many aspects. GCP will enforce tighter guidelines on ethical aspects of a clinical study. Higher standards will be required in terms of comprehensive documentation for the clinical protocol, record keeping, training, and facilities including computers. Quality assurance and inspections will ensure that these standards are achieved. The additional requirements of GCP are discussed and any advantage to the study subject. The impact of the new Directive within the Research Governance Framework of the UK Department of Health is reviewed.